The following is a summary of “Development models to predict complication and prognosis following liver resection for ...

"FDA grants ODD to Tempest’s hepatocellular carcinoma treatment" was originally created and published by Pharmaceutical ...

Liver cells attempt to shut down as a defense mechanism against cancer, but this strategy is not particularly effective.

Alcohol-associated hepatitis (AH) is a critical global health issue characterized by acute liver inflammation and an elevated ...

In an extremely rare case, an unnamed 69-year-old man who had cirrhosis and liver cancer underwent a liver transplant and ...

In an extremely rare case, an unnamed 69-year-old man who had cirrhosis and liver cancer underwent a liver transplant and ...

PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications • NAYA aiming to initiate clinical trials in early 2026 SARASOTA, Fla.

Patients with indeterminate chronic hepatitis B (CHB) phase are at risk of progressing to advanced liver disease and hepatocellular carcinoma (HCC), according to study results published in the Journal ...

PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications • ...

But the man’s condition worsened, progressing into cirrhosis and eventually hepatocellular carcinoma, also known as liver ...

BGB-10188 is under clinical development by BeiGene and currently in Phase II for Renal Cell Carcinoma. According to GlobalData, Phase II drugs for Renal Cell Carcinoma have a 29% phase transition ...

This manuscript offers valuable insights by identifying two distinct liver cancer subtypes through multi-omics integration and developing a robust prognostic model, validated across various datasets, ...